Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Source: nct - Pays: United Kingdom,Czech Republic,Israel,Belgium,United States,Canada,France,Korea, Republic of,Spain,Japan - Le promoteur: nct
nct
MAJ Il y a 5 ans
BUILD 3: Bosentan Use in Interstitial Lung Disease
BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.
Pays
Australia
,
Austria
,
Belgium
,
Canada
,
Croatia
,
Czech Republic
,
France
,
Germany
,
Ireland
,
Israel
,
Italy
,
Japan
,
Korea, Republic of
,
Netherlands
,
Serbia
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).
Pays
Australia
,
Belgium
,
Canada
,
Czech Republic
,
France
,
Germany
,
Ireland
,
Israel
,
Italy
,
Japan
,
Korea, Republic of
,
Spain
,
Switzerland
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1